返回 Agendas
Session 7: Quantitative Measures for Benefit-Risk Assessment
Session Chair(s)
Ram Tiwari, PHD, MS
Head of Statistical Methodology
Bristol Myres Squibb , United States
Frank W. Rockhold, PHD, MSC
Professor of Biostatistics
Duke Clinical Research Institute, Duke University Medical Center, United States
Panelists (joining the Speakers)
Speaker(s)
Quantitative Structured Benefit-Risk: The Current, the New and the Future
Ian Hirsch, PHD
Astrazeneca, United Kingdom
Respiratory/Infection Biologics and Vaccine Products Biometrics Strategy Lead
Bayesian Approaches to Quantitative Benefit-Risk Assessment: A Perspective for Better Decision Making
Yueqin Zhao, PHD
FDA, United States
Lead Mathematical Statistician, OB, OTS, CDER
Benefit-Risk Approaches for Hypothetical Risk
Marilyn A. Metcalf, PHD
GlaxoSmithKline, United States
Senior Director, Patient Focused Development, Global Medical
Telba Irony, PHD, MS, MSC
Janssen R&D, United States
Senior Scientific Director, Quantitative Sciences
Christy Chuang-Stein, PHD
Chuang-Stein Consulting, LLC, United States
Vice President, Head of Statistical Research and Consulting Center